Abstract
Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects. Among secondary osteoporosis, glucocorticoidinduced osteoporosis is the most common and severe form, and up to now prolonged glucocorticoid therapy has been considered the most important osteoporotic risk factor in rheumatic patients. However, it is now clear that the pathogenesis of osteoporosis in inflammatory rheumatic diseases is mediated by several factors. In particular, new discoveries within osteoimmunology concerning the complex relationship between bone and immunity, suggest that inflammation itself, through proinflammatory and osteoclastogenic cytokine overexpression, promotes bone resorption leading to increased skeletal fragility. Therefore, by controlling systemic inflammation, it is also possible to reduce the loss of bone mass which accompanies rheumatic diseases. From this point of view, we critically revisit the effects of glucocorticoids on bone in rheumatic diseases, in which they should be seen not just as an enemy of the bone health but eventually as a potential therapeutic tool capable of reducing the risk of osteoporosis by controlling disease activity and inflammation.
Keywords: Bone, glucocorticoid, inflammation, osteoporosis, rheumatic diseases, translational medicine.
Current Medicinal Chemistry
Title:Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?
Volume: 22 Issue: 5
Author(s): Fedra Ciccarelli, Massimo De Martinis and Lia Ginaldi
Affiliation:
Keywords: Bone, glucocorticoid, inflammation, osteoporosis, rheumatic diseases, translational medicine.
Abstract: Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects. Among secondary osteoporosis, glucocorticoidinduced osteoporosis is the most common and severe form, and up to now prolonged glucocorticoid therapy has been considered the most important osteoporotic risk factor in rheumatic patients. However, it is now clear that the pathogenesis of osteoporosis in inflammatory rheumatic diseases is mediated by several factors. In particular, new discoveries within osteoimmunology concerning the complex relationship between bone and immunity, suggest that inflammation itself, through proinflammatory and osteoclastogenic cytokine overexpression, promotes bone resorption leading to increased skeletal fragility. Therefore, by controlling systemic inflammation, it is also possible to reduce the loss of bone mass which accompanies rheumatic diseases. From this point of view, we critically revisit the effects of glucocorticoids on bone in rheumatic diseases, in which they should be seen not just as an enemy of the bone health but eventually as a potential therapeutic tool capable of reducing the risk of osteoporosis by controlling disease activity and inflammation.
Export Options
About this article
Cite this article as:
Ciccarelli Fedra, Martinis De Massimo and Ginaldi Lia, Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?, Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867321666141106125051
DOI https://dx.doi.org/10.2174/0929867321666141106125051 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Potential of Curcumin: From Chemistry and Mechanistic
Insight to Nanoformulations
Current Bioactive Compounds Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Topical Delivery of Cultured Stem Cells to Human Non-Healing Wounds: GMP Facility Development in an Academic Setting and FDA Requirements for an IND and Human Testing
Current Drug Delivery Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Clinical Genetics of Psoriasis
Current Genomics Pain-Relief Medication and Risk of Fractures
Current Drug Safety Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Metal-Based Antimicrobial Protease Inhibitors
Current Medicinal Chemistry Granulocyte Apoptosis and Macrophage Clearance of Apoptotic Cells as Targets for Pharmacological Intervention in Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Discovering the Potential of Plants in Wound Healing: A Mechanistic Review
Current Indian Science Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) The Importance of Rhodanine Scaffold in Medicinal Chemistry: A Comprehensive Overview
Mini-Reviews in Medicinal Chemistry Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Activities of 5, 6-Diaryl/heteroaryl-3-substituted-1, 2, 4- triazines as a Privileged Scaffold in Drug Development
Mini-Reviews in Medicinal Chemistry Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets